CRC associated with LS usually involves activation of the WNT/β-catenin signaling pathway due to secondary mutations in APC or β-catenin (CTNNB1), further advancing tumorigenic processes (9). This evidence concerns the gene CTNNB1 and colorectal carcinoma.